From GlobeNewswire: 2025-06-10 09:20:00

The global Albumin Market was valued at USD 6.65 billion in 2023 and is projected to reach USD 11.02 billion by 2032, with a CAGR of 6.58% during 2024-2032. The market is driven by the pharmaceutical and biotechnology industries, increasing global healthcare demands, and clinical applications.

In the U.S., the albumin market was estimated at USD 4.35 billion in 2023 and is expected to reach USD 6.97 billion by 2032, with a CAGR of 6.13% during 2024-2032. North America leads the global market due to well-established healthcare infrastructure and high adoption of albumin in clinical settings.

The human serum albumin segment dominated the albumin market in 2024 with a 54.6% market share, driven by its applications in treating medical conditions like liver cirrhosis, burns, shock, and hypoalbuminemia. The therapeutics segment held a 68.1% market share in 2024, with high demand for albumin in treating critical medical conditions.

Hospitals & clinics captured around 82.2% market share in the albumin market in 2024, due to the high number of patient admissions requiring albumin therapy for conditions like liver failure, burns, trauma, and major surgeries. North America leads the market, while the Asia Pacific region is expected to register the fastest growth due to increasing healthcare expenditure and demand for low-cost therapeutics.



Read more at GlobeNewswire: Albumin Market Set to Reach USD 11.02 Billion by 2032,